Dahan Rony, Korman Alan J
Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Vir Biotechnology, San Francisco, CA, 94158, USA.
Trends Mol Med. 2025 Jun;31(6):501-505. doi: 10.1016/j.molmed.2024.10.008. Epub 2024 Nov 1.
The development of checkpoint antibodies for cancer therapy has been guided by the principle of blocking T cell inhibitory signals. Recognition of the role of the Fc domain in therapeutic activities, through the depletion of immunosuppressive populations and myeloid cell activation, prompts a shift toward the development of optimized Fc-engineered checkpoint antibodies.
癌症治疗检查点抗体的开发一直以阻断T细胞抑制信号的原则为指导。通过消耗免疫抑制群体和激活髓样细胞，认识到Fc结构域在治疗活性中的作用，促使人们转向开发优化的Fc工程化检查点抗体。
